When is dual bronchodilation indicated in COPD?

References

• VogelmeierCFCrinerGJMartinezFJGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 report: GOLD executive summaryEur Respir J2017493170021428182564
   PubMed Web of Science ®Google Scholar
• MiravitllesMSoler-CataluñaJJCalleMSpanish COPD guidelines (GesEPOC) 2017: pharmacological treatment of stable chronic obstructive pulmonary diseaseArch Bronconeumol20175332433528477954
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest20021221475512114338
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• RossiAKristufekPLevineBEComparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPDChest200212141058106911948033
   PubMed Web of Science ®Google Scholar
• ChapmanKRRennardSIDograALong-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled studyChest20111401687521349928
   PubMed Web of Science ®Google Scholar
• KerwinEMD’UrzoADGelbAFLakkisHGarciaGECaractaCFEfficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD2012929010122320148
   PubMedGoogle Scholar
• BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J Chron Obstruct Pulmon Dis2012750351322973092
   PubMed Web of Science ®Google Scholar
• MaltaisFCelliBCasaburiRAclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPDRespir Med2011105458058721183326
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• O’DonnellDECasaburiRVinckenWEffect of indacaterol on exercise endurance and lung hyperinflation in COPDRespir Med201110571030103621498063
   PubMed Web of Science ®Google Scholar
• HalpinDMVogelmeierCPieperMPMetzdorfNRichardFAnzuetoAEffect of tiotropium on COPD exacerbations: a systematic reviewRespir Med20161141827109805
   PubMed Web of Science ®Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990525210450
   PubMed Web of Science ®Google Scholar
• ZuwallackRHow are you doing? What are you doing? Differing perspectives in the assessment of individuals with COPDCOPD20074329329717729076
   PubMedGoogle Scholar
• ChapmanKBatemanEGallagherNHuHBanerjiDQVA149 once daily improves lung function, dyspnoea and health status independent of prior medications and disease severity: the SHINE studyThorax201368Suppl 3A182A183 Abstract P234
   Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMMergelVLeslbaumARCaractaCFEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT studyRespir Med2014108458459224534204
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• JonesPWRennardSTabbererMRileyJHVahdati-BolouriMBarnesNCInterpreting patient-reported outcomes from clinical trials in COPD: a discussionInt J Chron Obstruct Pulmon Dis2016113069307827994447
   PubMed Web of Science ®Google Scholar
• SinghDNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesBr J Clin Pharmacol201579569570825377687
   PubMed Web of Science ®Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• KerwinEMKalbergCJGalkinDVUmeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week studyInt J Chron Obstruct Pulmon Dis20171274575528280319
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDMunzuCKilbrideSChurchAMagnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trialsRespir Med2016112657426797016
   PubMed Web of Science ®Google Scholar
• DonohueJFResponse to letter to the editor: improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med20161108126689766
   PubMed Web of Science ®Google Scholar
• BanerjiDPatalanoFImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2016110798026211886
   PubMed Web of Science ®Google Scholar
• VogelmeierCAlamian-MattheisMGreulichTEfficacy and safety of the direct switch from various previous treatments to glycopyrronium or indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL studyPresented at the British Thoracic SocietyLondon, UK7–9 December 20162016
   Google Scholar
• TroostersTvan der MolenTPolkeyMImproving physical activity in COPD: towards a new paradigmRespir Res20131411524229341
   PubMed Web of Science ®Google Scholar
• TroostersTLavoieKLeidyNEffects of bronchodilator therapy and exercise training, added to a self-management behaviour-modification programme, on physical activity in COPDPresented at the European Respiratory Society (ERS) International CongressLondon, United Kingdom3–7 September 2016 Poster A7132016
   Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis20148616918125452426
   PubMed Web of Science ®Google Scholar
• BeehKMKornSBeierJQVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT studyThorax201267Suppl 2A147 Abstract P191
   Web of Science ®Google Scholar
• TroostersTBourbeauJMaltaisFEnhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study designBMJ Open201664e010106
   Web of Science ®Google Scholar
• WatzHMailanderCBaierMKirstenAEffects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (the MOVE study)BMC Pulm Med2016169527301417
   PubMed Web of Science ®Google Scholar
• BatemanEDMahlerDAVogelmeierCFWedzichaJAPatalanoFBanerjiDRecent advances in COPD disease management with fixed-dose long-acting combination therapiesExpert Rev Respir Med20148335737924802656
   PubMed Web of Science ®Google Scholar
• MahlerDAKeiningerDLMezziKFogelRBanerjiDEfficacy of indacaterol/glycopyrronium in patients with COPD who have increased dyspnea with daily activitiesChronic Obstr Pulm Dis (Miami)201634758768
   Google Scholar
• MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax201267978178822544891
   PubMed Web of Science ®Google Scholar
• VogelmeierCBatemanEDD’AndreaPOnce-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the ILLUMINATE studyAm J Respir Crit Care Med20141891A3763
   Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2015109787088126006754
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• VogelmeierCPaggiaroPLDorcaJEfficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD studyEur Respir J20164841030103927492833
   PubMed Web of Science ®Google Scholar
• KostikasKClemensAPatalanoFThe asthma-COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?Int J Chron Obstruct Pulmon Dis2016111297130627366057
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• AnzuetoAFergusonGTFeldmanGEffect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesCOPD20096532032919863361
   PubMedGoogle Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJABrookRDFluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialLancet2016387100301817182627203508
   PubMed Web of Science ®Google Scholar
• PascoeSJLipsonDALocantoreNA phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocolEur Respir J201648232033027418551
   PubMed Web of Science ®Google Scholar
• Chiesi Farmaceutici2-Arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients (TRIBUTE) Available from: https://clinicaltrials.gov/ct2/show/NCT2579850. NLM identifier: NCT2579850Accessed February 9, 2017
   Google Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• SiddiquiSHGuasconiAVestboJBlood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015192452352526051430
   PubMed Web of Science ®Google Scholar
• DonohueJFAnother choice for prevention of COPD exacerbationsN Engl J Med2016374232284228627181835
   PubMed Web of Science ®Google Scholar
• WatzHTetzlaffKWoutersEFBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
   PubMed Web of Science ®Google Scholar
• CalverleyPTetzlaffKVogelmeierCEvaluating blood eosinophils and exacerbation history to predict ICS response in COPDPoster presented at: European Respiratory (ERS) Society International CongressSeptember 3–7, 2016London Poster OA1973
   Google Scholar
• VestboJLangePPrevention of COPD exacerbations: medications and other controversiesERJ Open Research201511 pii:00011–02015
   Google Scholar
• VestboJVogelmeierCSmallMHigginsVUnderstanding the GOLD 2011 strategy as applied to a real-world COPD populationRespir Med2014108572973624675239
   PubMed Web of Science ®Google Scholar
• BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis2015102207221726527869
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of COPDBethesda, MDGOLD2016 Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/Accessed February 05, 2016
   Google Scholar
• FesticEBansalVGuptaEScanlonPDAssociation of inhaled corticosteroids with incident pneumonia and mortality in COPD patients: systematic review and meta-analysisCOPD201513331232626645797
   PubMedGoogle Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• MiravitllesMD’UrzoASinghDKoblizekVPharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewRespir Res201617111227613392
   PubMed Web of Science ®Google Scholar
• Chronic obstructive pulmonary diseaseManagement of chronic obstructive pulmonary disease in adults in primary and secondary careNICE clinical guideline 101 (partial update) Updated June 2010. Available from: https://www.nice.org.uk/guidance/cg101Accessed June 5, 2017
   Google Scholar
• GlaxoSmithKlineCOPD Assessment Test: Expert Guidance on Frequently Asked QuestionsBrentford, UKGSK2012 Available from: http://www.catestonline.org/images/UserGuides/CATHCPUser%20guideEn.pdf
   Google Scholar
• JonesPWBrusselleGDal NegroRWProperties of the COPD assessment test in a cross-sectional European studyEur Respir J2011381293521565915
   PubMed Web of Science ®Google Scholar
• JenkinsCRPostmaDSAnzuetoARReliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary diseaseBMC Pulm Med2015159726293575
   PubMed Web of Science ®Google Scholar
• JonesPWCOPD assessment test: rationale, development, validation and performanceCOPD201310226927123547637
   PubMedGoogle Scholar
• TsiligianniIGvan der MolenTMoraitakiDAssessing health status in COPD: a head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ)BMC Pulm Med2012122022607459
   PubMed Web of Science ®Google Scholar
• StentonCThe MRC breathlessness scaleOccup Med (Lond)200858322622718441368
   PubMed Web of Science ®Google Scholar
• PriceDSmallMMilliganGHigginsVGilEGEstruchJImpact of night-time symptoms in COPD: a real-world study in five European countriesInt J Chron Obstruct Pulmon Dis2013859560324348032
   PubMed Web of Science ®Google Scholar
• AgustiAHednerJMarinJMBarbéFCazzolaMRennardSNighttime symptoms: a forgotten dimension of COPDEur Respir Rev20112012118319421881146
   PubMedGoogle Scholar
• MiravitllesMWorthHSoler-CataluñaJJObservational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS studyRespir Res20141512225331383
   PubMed Web of Science ®Google Scholar
• LôtvallJCosioBGIqbalAIndacaterol once-daily improves day-and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropiumEur Respir J200934Suppl 53346S Abstract P2029
   Google Scholar
• Soler-CataluñaJJAlcazar-NavarreteBMiravitllesMThe concept of control of COPD in clinical practiceInt J Chron Obstruct Pulmon Dis201491397140525548521
   PubMed Web of Science ®Google Scholar
• AgustiACalverleyPMCelliBCharacterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res20101112220831787
   PubMed Web of Science ®Google Scholar
• PavordIDLettisSLocantoreNBlood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPDThorax201671211812526585525
   PubMed Web of Science ®Google Scholar
• MartinezFJRabeKFSethiSEffect of roflumilast and inhaled corticosteroid/long-acting β2-agonist on chronic obstructive pulmonary disease exacerbations (RE2SPOND): a randomized clinical trialAm J Respir Crit Care Med2016194555956727585384
   PubMed Web of Science ®Google Scholar
• ChapmanKRBatemanEDChenHTHuHLFogelRBanerjiDQVA149 improves lung function, dyspnea, and health status independent of previously prescribed medications and COPD severity: a subgroup analysis from the SHINE and ILLUMINATE studiesJ COPD Foundation2015214860
   Google Scholar
• AlwashmiMHawboldtJDavisEMarraCGambleJMAshourWAThe effect of smartphone interventions on patients with chronic obstructive pulmonary disease exacerbations: a systematic review and meta-analysisJMIR Mhealth Uhealth201643e10527589898
   PubMed Web of Science ®Google Scholar
• EstebanCMorazaJIriberriMOutcomes of a telemonitoring-based program (telEPOC) in frequently hospitalized COPD patientsInt J Chron Obstruct Pulmon Dis2016112919293027920519
   PubMed Web of Science ®Google Scholar
• HalpinDBanksLMartelloAWorking together to go ‘beyond the pill’: building a virtuous network of collaboratorsBMJ Innovations2016213
   Google Scholar
• StatistaSmartphones: statistics and facts Available from: https://www.statista.com/topics/840/smartphonesAccessed May 17, 2017
   Google Scholar
• RossiAGuerrieroMCorradoAReal-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Eur Respir J201342Suppl 57143S144S Abstract P4144
   Google Scholar
• MagnoniMSRizziAViscontiADonnerCFAIMAR survey on COPD phenotypesMultidiscip Respir Med2014911624635848
   PubMedGoogle Scholar
• CazzolaMRoglianiPMateraMGEscalation and de-escalation of therapy in COPD: myths, realities and perspectivesDrugs201575141575158526316169
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• BeierJvan NoordJDeansASafety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patientsInt J Chron Obstruct Pulmon Dis2012715316422419863
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest2014145598199124385182
   PubMed Web of Science ®Google Scholar
• HananiaNABootaAKerwinETomlinsonLDenis-MizeKEfficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trialDrugs20096991205121619537837
   PubMed Web of Science ®Google Scholar
• HoshinoMOhtawaJComputed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patientsRespirology201419340341024708031
   PubMed Web of Science ®Google Scholar
• ImranMChhabraSKotwaniACombinations of long acting β2 agonists to tiotropium: a randomized, double-blind, placebo-controlled, active-drug controlled, parallel design academic clinical trial in moderate COPD male patientsArch Pharm Pract2015621923
   Google Scholar
• JayaramLWongCMcAuleySReaHZengIO’DochartaighCCombined therapy with tiotropium and formoterol in chronic obstructive pulmonary disease: effect on the 6-minute walk testCOPD201310446647223875741
   PubMedGoogle Scholar
• SalviSBrashierBGothiDBronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPDPulm Pharmacol Ther2014271909523752057
   PubMed Web of Science ®Google Scholar
• TashkinDPLittnerMAndrewsCPTomlinsonLRinehartMDenis-MizeKConcomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trialRespir Med2008102447948718258423
   PubMed Web of Science ®Google Scholar
• TashkinDPPearleJIezzoniDVargheseSTFormoterol and tiotropium compared with tiotropium alone for treatment of COPDCOPD200961172519229704
   PubMedGoogle Scholar
• TashkinDPDonohueJFMahlerDAEffects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPDRespir Med2009103451652419208459
   PubMed Web of Science ®Google Scholar
• TerzanoCPetroianniAContiVRational timing of combination therapy with tiotropium and formoterol in moderate and severe COPDRespir Med2008102121701170718760583
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest2006129350951716537846
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensECombining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptomsRespir Med20101047995100420303247
   PubMed Web of Science ®Google Scholar
• VinckenWAumannJChenHHenleyMMcBryanDGoyalPEfficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 studyInt J Chron Obstruct Pulmon Dis2014921521824596459
   PubMed Web of Science ®Google Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med2008102111511152018804362
   PubMed Web of Science ®Google Scholar
• ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat and tiotropium HandiHaler in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar